La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Cyclopharm Résultats passés

Passé contrôle des critères 0/6

Informations clés

-19.3%

Taux de croissance des bénéfices

-12.9%

Taux de croissance du BPA

Medical Equipment Croissance de l'industrie	5.8%
Taux de croissance des recettes	13.7%
Rendement des fonds propres	-14.6%
Marge nette	-17.3%
Dernière mise à jour des bénéfices	31 Dec 2023

Mises à jour récentes des performances passées

Recent updates

What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash

Oct 28

Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

Mar 02

We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

Oct 22

Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

Jun 29

Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

Apr 27

Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic

Mar 01

Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment

Feb 07

Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders?

Jan 02

We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate

Dec 06

Ventilation des recettes et des dépenses

Comment Cyclopharm gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

ASX:CYC Recettes, dépenses et bénéfices (AUD Millions )
Date	Recettes	Les revenus	Dépenses G+A	Dépenses de R&D
31 Dec 23	27	-5	21	4
30 Sep 23	28	-6	20	5
30 Jun 23	29	-7	19	6
31 Mar 23	27	-7	19	5
31 Dec 22	25	-7	19	3
30 Sep 22	24	-5	18	2
30 Jun 22	23	-4	18	1
31 Mar 22	21	-4	17	1
31 Dec 21	20	-5	17	2
30 Sep 21	20	-5	16	2
30 Jun 21	20	-4	16	3
31 Mar 21	19	-5	15	3
31 Dec 20	18	-6	14	4
30 Sep 20	17	-6	14	4
30 Jun 20	16	-6	13	4
31 Mar 20	17	-4	13	4
31 Dec 19	17	-3	12	4
30 Sep 19	16	-3	11	4
30 Jun 19	16	-2	10	4
31 Mar 19	16	-1	10	4
31 Dec 18	16	0	9	3
30 Sep 18	16	0	9	3
30 Jun 18	16	-1	9	3
31 Mar 18	16	-1	9	3
31 Dec 17	16	-2	9	3
30 Sep 17	15	-1	8	3
30 Jun 17	14	-1	8	2
31 Mar 17	15	0	8	2
31 Dec 16	15	1	8	1
30 Sep 16	14	3	7	1
30 Jun 16	14	5	7	1
31 Mar 16	13	5	7	1
31 Dec 15	13	5	6	1
30 Sep 15	12	4	6	1
30 Jun 15	11	3	6	1
31 Mar 15	11	4	7	1
31 Dec 14	12	4	7	0
30 Sep 14	13	-2	7	0
30 Jun 14	14	-8	8	0
31 Mar 14	13	-9	8	0
31 Dec 13	12	-10	8	0
30 Sep 13	12	-6	7	0

Augmentation de la marge bénéficiaire: CYC n'est actuellement pas rentable.

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: CYC n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 19.3% par an.

Cyclopharm Résultats passés

Passé contrôle des critères 0/6

Informations clés

Mises à jour récentes des performances passées

Full year 2023 earnings: EPS exceeds analyst expectations

First half 2023 earnings released: AU$0.032 loss per share (vs AU$0.028 loss in 1H 2022)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

First half 2022 earnings released: AU$0.028 loss per share (vs AU$0.045 loss in 1H 2021)

Full year 2021 earnings: Revenues exceed analyst expectations

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

New minor risk - Shareholder dilution

Cyclopharm Limited has completed a Follow-on Equity Offering in the amount of AUD 20.000001 million.

Cyclopharm Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

New minor risk - Market cap size

Consensus revenue estimates fall by 14%

Cyclopharm Limited, Annual General Meeting, May 27, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Cyclopharm Limited Appoints John Wigglesworth to its Board as Non- Executive Director

Consensus EPS estimates fall by 11%

CEO, MD exercised options to buy AU$402k worth of stock.

What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash

Forecast breakeven date pushed back to 2025

First half 2023 earnings released: AU$0.032 loss per share (vs AU$0.028 loss in 1H 2022)

Cyclopharm Limited Declares Unfranked Interim Dividend for the Six Months Ended June 30, 2023, Payable on 11 September 2023

Consensus estimates of losses per share improve by 13%

Is Cyclopharm Limited (ASX:CYC) Trading At A 25% Discount?

Companies Like Cyclopharm (ASX:CYC) Are In A Position To Invest In Growth

Consensus EPS estimates fall by 153%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclopharm Limited Announces Dividend for A Period of Six Months Ended December 31, 2022, Payable on April 4 2023

Less than half of directors are independent

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Less than half of directors are independent

Cyclopharm Limited Appoints Gregory King as A Non-Executive Director

Cyclopharm Limited Appoints Kevin Barrow as A Nonexecutive Director

First half 2022 earnings released: AU$0.028 loss per share (vs AU$0.045 loss in 1H 2021)

Cyclopharm Limited Declares an Unfranked Dividend for the Half Year Ended June 30, 2022, Payable on 12 September 2022

Consensus revenue estimates increase by 10%

Cyclopharm Limited Announces Independent Multicentre Study Highlights the Benefits of Technegas in Diagnosing Pulmonary Embolism in Growing Covid-19 Patient Population

Cyclopharm Limited Provides Sales Guidance for the Half Year Ended 30 June 2022

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Cyclopharm Limited Announces Technegas Used in Diagnosing Long COVID

Full year 2021 earnings: Revenues exceed analyst expectations

Analyst Forecasts For Cyclopharm Limited (ASX:CYC) Are Surging Higher

Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

Consensus revenue estimates increase by 14%

Forecast to breakeven in 2024

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclopharm Limited Announces Dividend for Period of Six Months Ended December 31, 2021, Payable on April 12, 2022

Cyclopharm Limited Provides Earnings Guidance for the Full Year 2021

Less than half of directors are independent

We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

First half 2021 earnings released: AU$0.045 loss per share (vs AU$0.074 loss in 1H 2020)

Cyclopharm Limited Provides Unaudited Revenue Guidance for the First Half of 2021

Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

Consensus revenue estimates fall to AU$16.5m

Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

Full year 2020 earnings released: AU$0.079 loss per share (vs AU$0.043 loss in FY 2019)

Cyclopharm Limited provides Confirmation of Technegas USFDA Timetable

Analysts increase revenue estimates to AU$18.6m

Cyclopharm Limited, Annual General Meeting, May 04, 2021

Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic

Full year 2020 earnings released: AU$0.079 loss per share (vs AU$0.043 loss in FY 2019)

Revenue beats expectations, earnings disappoint

Cyclopharm Limited Provides Update on USFDA Approval to Distribute Technegas in the USA in 2021

Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment

New 90-day high: AU$3.10

Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders?

We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate

New 90-day high: AU$2.63

Cyclopharm Limited Announces A New Research Collaboration with Mcmasters University

New 90-day high - AU$1.59

First half earnings released

Ventilation des recettes et des dépenses

Historique des gains et des recettes

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Rendement des fonds propres

Rendement des actifs